HeartFlow represents the holy grail of health tech: AI that actually gets FDA clearance. But with $927M burned and only 52K monthly visitors, the conversion from R&D to revenue remains the industry's trillion-dollar question.

"HeartFlow isn't selling software—they're selling the elimination of unnecessary cath labs. That's a $30B opportunity, but execution requires hospital sales cycles measured in years, not quarters."

The tech stack tells a story of modernization—Vite, Tailwind, GSAP—but this is lipstick on a B2B2C pig. Their real innovation isn't the website; it's the CT-to-FFR pipeline that turns 20-minute invasive procedures into 15-minute non-invasive predictions. The question isn't whether it works (FDA says yes), but whether cardiologists will trust AI over their own hands.

• Enterprise motion dominates: 80% of traffic is likely US-based, institutional buyers
• CEO John Farquhar brings the playbook from his Kaiser Permanente days—this is healthcare insider execution
• The 'HeartFlow Santa Rosa' search reveals their operational base; they're not a SF startup, they're a real company with real offices